Back to User profile » Dr Patrick Darken
Papers published by Dr Patrick Darken:
Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies for Patients with COPD and Phenotypic Features of Asthma: A Pooled Post Hoc Analysis of KRONOS and ETHOS
Muro S, Seki M, Hurst JR, Petullo D, Marshall J, Bowen K, Darken PF, Duncan EA, Megally A, Patel M
International Journal of Chronic Obstructive Pulmonary Disease 2024, 19:2729-2737
Published Date: 12 December 2024
Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS
Bafadhel M, Rabe KF, Martinez FJ, Singh D, Darken P, Jenkins M, Aurivillius M, Patel M, Dorinsky P
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:3061-3073
Published Date: 6 December 2022
Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS
Martinez FJ, Ferguson GT, Bourne E, Ballal S, Darken P, Aurivillius M, Dorinsky P, Reisner C
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:179-189
Published Date: 28 January 2021
The Long-Term Burden of COPD Exacerbations During Maintenance Therapy and Lung Function Decline
Kerkhof M, Voorham J, Dorinsky P, Cabrera C, Darken P, Kocks JWH, Sadatsafavi M, Sin DD, Carter V, Price DB
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:1909-1918
Published Date: 6 August 2020
Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD
Reisner C, Pearle J, Kerwin EM, St Rose E, Darken P
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:1965-1977
Published Date: 19 June 2018